[1] Chinese Society of Hepatology and Chinese Society of Infectious Disease,Chinese Medical Association. The guideline of prevention and treatment for hepatitis C:A 2015 update[J]. J Clin Hepatol,2015,31(12):1961-1979.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.丙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1961-1979.
|
[2] THOMAS DL. Global control of hepatitis C:Where challenge meets opportunity[J]. Nat Med,2013,19(7):850-858.
|
[3] SMITH DB,BUKH J,KUIKEN C,et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes:Updated criteria and genotype assignment web resource[J].Hepatology,2014,59(1):318-327.
|
[4] XU R,TONG W,GU L,et al. A panel of 16 full-length HCV genomes was characterized in China belonging to genotypes 1-6 including subtype 2f and two novel genotype 6 variants[J]. Infect Genet Evol,2013,20:225-229.
|
[5] MIAO ZQ. Application of direct-acting antiviral agents in treatment of hepatitis C[J]. Mod Pract Med,2018,30(3):284-286.(in Chinese)缪正秋.直接抗病毒药物治疗丙型肝炎的应用[J].现代实用医学,2018,30(3):284-286.
|
[6] AN ZY,DING Y,DOU XG. Selection and evaluation of treatment regimens with direct-acting antiviral agents for patients with chronic hepatitis C in the real world in China[J]. J Clin Hepatol,2018,34(2):233-237.(in Chinese)安子英,丁洋,窦晓光.我国慢性丙型肝炎患者真实世界中直接抗病毒药物治疗方案的选择与评价[J].临床肝胆病杂志,2018,34(2):233-237.
|
[7] QUAN M,XING HC. Effects of hepatitis C virus resistance associated variants on the efficacy of direct-acting antiviral agents[J/CD]. Chin J of Liver Diseases(Electronic Version),2018,10(3):32-36.(in Chinese)全敏,邢卉春.丙型肝炎病毒耐药相关变异对直接抗病毒药物疗效的影响[J/CD].中国肝脏病杂志(电子版),2018,10(3):32-36.
|
[8] KJELLIN M,KILENG H,AKABERI D,et al. Effect of the baseline Y93H resistance-associated substitution in HCV genotype3 for direct-acting antiviral treatment:Real-life experience from a multicenter study in Sweden and Norway[J]. Scand J Gastroenterol,2019,54(8):1042-1050.
|
[9] NG TF,KONDOV NO,DENG X,et al. A metagenomics and case-control study to identify viruses associated with bovine respiratory disease[J]. J Virol,2015,89(10):5340-5349.
|
[10] THOMSON E,IP CL,BADHAN A,et al. Comparison of nextgeneration sequencing technologies for comprehensive assessment of full-length hepatitis C viral genomes[J]. J Clin Microbiol,2016,54(10):2470-2484.
|
[11] RONG X,XU R,XIONG H,et al. Increased prevalence of hepatitis C virus subtype 6a in China:A comparison between2004-2007 and 2008-2011[J]. Arch Virol,2014,159(12):3231-3237.
|
[12] European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016[J]. J Hepatol,2017,66(1):153-194.
|
[13] PERALES C,CHEN Q,SORIA ME,et al. Baseline hepatitis C virus resistance-associated substitutions present at frequencies lower than 15%may be clinically significant[J]. Infect Drug Resist,2018,11:2207-2210.
|
[14] KAI Y,HIKITA H,MORISHITA N,et al. Baseline quasispecies selection and novel mutations contribute to emerging resistance-associated substitutions in hepatitis C virus after direct-acting antiviral treatment[J]. Sci Rep,2017,7:41660.
|
[15] NAKANO K,SHIROMA A,SHIMOJI M,et al. Advantages of genome sequencing by long-read sequencer using SMRT technology in medical area[J]. Hum Cell,2017,30(3):149-161.
|
[1] | Wenjing NI, Nan GENG, Xue BAI, Jie LI. An excerpt of EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease in 2024[J]. Journal of Clinical Hepatology, 2024, 40(8): 1567-1574. doi: 10.12449/JCH240810 |
[2] | Xiaoyong DUO, Shijie ZHANG, Hongwei ZHANG, Jing YANG, Wenqiang WANG, Linzhi YU, Baocai ZHANG, Yicheng ZHUO, Yunchao JIA, Yan PENG, Shuai HU. Association between gallstones and metabolic syndrome in southern Xinjiang, China[J]. Journal of Clinical Hepatology, 2022, 38(8): 1859-1864. doi: 10.3969/j.issn.1001-5256.2022.08.026 |
[3] | CHEN Huan, LI Ting, WANG ZiJie, WANG ZhongQiong, LUO Gang, DENG MingMing. Influence of metabolic syndrome and its components on the prognosis of patients with pancreatic cancer[J]. Journal of Clinical Hepatology, 2020, 36(12): 2788-2794. doi: 10.3969/j.issn.1001-5256.2020.12.029 |
[4] | Tian Tian, Hu WenWei, Li Xue, Li Ji, Zhang Dan, Li ZhangZheng. Metabolic characteristics of nonalcoholic fatty liver disease and related risk factors in non-obese population[J]. Journal of Clinical Hepatology, 2020, 36(6): 1310-1313. doi: 10.3969/j.issn.1001-5256.2020.06.024 |
[5] | Niu ChunYan, Liu Qin, Luo XiaoChun. Reexamination of the diagnosis of fatty liver disease under the background of disease spectrum progression[J]. Journal of Clinical Hepatology, 2020, 36(10): 2356-2359. doi: 10.3969/j.issn.1001-5256.2020.10.043 |
[6] | Chinese Society of EndocrinologyChinese Medical Association. Consensus for diagnosis and treatment of nonalcoholic fatty liver diseases and metabolic disorders (2nd Edition)[J]. Journal of Clinical Hepatology, 2018, 34(10): 2103-2108. doi: 10.3969/j.issn.1001-5256.2018.10.010 |
[7] | Wu QiQi, Ma Yan, Wang XiaoBo, Xu Qiang, Wang Yan, Bai Li. Influence of metabolic syndrome on significant hepatic fibrosis in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2018, 34(12): 2572-2577. doi: 10.3969/j.issn.1001-5256.2018.12.013 |
[8] | Zhou BingBing, Wang XueMei, Zhang Qian, Xu ShiYi, Dan ZhongYan, Lai YaXin, Wang HaoYu. Association between metabolic syndrome and gallstones[J]. Journal of Clinical Hepatology, 2017, 33(5): 880-882. doi: 10.3969/j.issn.1001-5256.2017.05.017 |
[9] | Xu BeiBei, Wang BingYuan. Nonalcoholic fatty liver disease and serum uric acid[J]. Journal of Clinical Hepatology, 2016, 32(3): 437-441. doi: 10.3969/j.issn.1001-5256.2016.03.007 |
[10] | Li LiangPing. Nonalcoholic fatty liver disease and hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(3): 432-436. doi: 10.3969/j.issn.1001-5256.2016.03.006 |
[11] | Fan JianGao, Yan ShiYan. Metabolic syndrome and fatty liver[J]. Journal of Clinical Hepatology, 2016, 32(3): 407-410. doi: 10.3969/j.issn.1001-5256.2016.03.001 |
[12] | Zhao HongXin, Yan Rong, Niu ChunYan, Zhou YongLi, Wang Jia, Cao RuiQi. Prevalence and associated risk factors for obesity and nonalcoholic fatty liver disease in adolescents in Xi′an, Shaanxi province, China[J]. Journal of Clinical Hepatology, 2015, 31(8): 1248-1251. doi: 10.3969/j.issn.1001-5256.2015.08.016 |
[13] | Huang Ying, Chen Hong. Research progress in association between nonalcoholic fatty liver disease and gallstone disease[J]. Journal of Clinical Hepatology, 2014, 30(11): 1217-1220. doi: 10.3969/j.issn.1001-5256.2014.11.033 |
[14] | Fan JianGao, Zhu ChanYan. Strengthening research on relationship between metabolic syndrome and chronic liver disease[J]. Journal of Clinical Hepatology, 2013, 29(12): 881-884. doi: 10.3969/j.issn.1001-5256.2013.12.001 |
[15] | Yan Jie, Xie Wen. Relationship between metabolic syndrome and chronic hepatitis C[J]. Journal of Clinical Hepatology, 2013, 29(12): 887-889. doi: 10.3969/j.issn.1001-5256.2013.12.003 |
[16] | Li LiangPing, Zhong Huang. The study of cytokeratin 18 fragments and inflammation related factors in non-alcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2012, 28(5): 359-363. |
[17] | Zhang YiNing, Du HongWei, Liu YanJun, Wang ChaoXia. The diagnosis and risk factors for evaluation of nonalcoholic fatty liver disease in children and adolescents[J]. Journal of Clinical Hepatology, 2011, 27(7): 690-693. |
[18] | Wu Tao, Yin ShouYi, Wang HongZhang, Zhang Hong, Jia Wei, Ji Guang. The clinical features and risk factors of patient with metabolic syndrome combined with non-alcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2011, 27(10): 1036-1040. |
[19] | Ruan JianWen, Yang Jing, Gao LiJuan. Advances in the relationship between metabolic syndrome and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2011, 27(10): 1102-1105. |
[20] | Niu ChunYan, Yan Rong, Tian Yu, Ma HuiXia, Jiao ShuJiang. The prevalence of fatty liver disease and its relationship with metabolic syndrome[J]. Journal of Clinical Hepatology, 2010, 26(2): 167-169. |